Phase 2 N=22 Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=418 Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trials
Malignant Neoplasm
Primary: Preparedness for Decision Making About Clinical Trial Participation, Measured Using Scores From the Preparation for Decision Making Scale — 71.3; 71.2 percentage of PDMS…
Phase 3 N=90 First Time Use of SD-809 in Huntington Disease
Chorea
Primary: Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12 — -4.42; -1.93 Units on a scale — p=<0.0001
N/A N=1,011 Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis
Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives
N/A N=97 Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations
Suicide · Suicidal Ideation
Primary: Estimated Proportion of Participants With Suicide Attempt — 0.19; 0.03; 0.06 estimated proportion of participants — p=.082
N/A N=25,038 Risk Factors Predicting Serious Complications With Laparoscopic Gastric Bypass Surgery
Postoperative Complications
Primary: Serious Complications — 630 Participants
Phase 2 N=37 Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Spinal and Bulbar Muscular Atrophy
Primary: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability — 2; 4; 2; 1 Participants
Phase 2 N=102 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -0.3; -3.4 units on a scale — p=<.0001
Phase 3 N=15,828 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Atherosclerosis
Primary: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial…
N/A N=8 Case Series of New Alloplastic Bone Graft Material
Periodontology · Oral Surgery
Primary: Percentage Change in Radiographic Measurement of Alveolar Ridge Height — 1.2 percentage of change
Phase 1 N=16 Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone
Healthy Subjects
Primary: Maximum Plasma Concentration (Cmax) of Infacort vs Hydrocortisone — 601.843; 622.384 nmol/L
Phase 3 N=246 Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Diffuse Large B-Cell Lymphoma
Primary: Event Free Survival — 65; 62 percentage of EFS at 3 years follow-up — p=<0.05
Phase 2 N=275 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Fallopian Tube Cancer · Metastatic Cancer · Ovarian Cancer
Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065
Phase 2 N=9 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
Single Umbilical Cord Blood Transplantation · Non-myeloablative Conditioning · Acute Lymphocytic Leukemia
Primary: Absence of Graft Failure at Day 42 — 0 Participants
N/A N=14 Nudging Guideline-concordant Antibiotic Prescribing Using Public Commitments
Acute Respiratory Infections (ARIs)
Primary: Inappropriate Antibiotic Prescribing for Patients With Acute Respiratory Infections (ARI) — 33.7; 52.7 inappropriate prescribing events